Purpose of this Study
We are doing this study to see if the study drug, PT886, with or without chemotherapy and/or pembrolizumab, is a safe and effective option for gastric and pancreatic cancer. We are also trying to find the best dose of the study drug to use.
Who Can Participate?
Eligibility
Adults ages 18+ who are diagnosed with an advanced or metastatic cancer of the following types:
- Gastric or gastroesophageal junction adenocarcinoma; OR
- Pancreatic ductal adenocaricnoma
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will:
- Receive infusions of PT886 every 1 to 3 weeks
- Depending on which arm of the study you are in, you may also get chemotherapy and/or pembrolizumab
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
[PT886X1101] A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab
Principal Investigator
Nicholas
DeVito
Protocol Number
PRO00116720
NCT ID
NCT05482893
Phase
I/II
Enrollment Status
Open to Enrollment